Manufactures and sells finished pharmaceutical formulations and active pharmaceutical ingredients (APIs) across global markets, generating ₹33,653 cr in FY26 revenue at a 21.6% EBITDA margin. The largest revenue streams are US formulations (Q4 FY26 at $387M, targeting a $2B milestone over the next 1–2 years) and Europe formulations, which crossed €1B annual revenue in FY26 with Q4 revenue of €261M. Growth markets were up 25% YoY in Q4 FY26, while India domestic formulations have been transferred to a wholly owned subsidiary called Auropharm Limited effective July 1, 2026. The company is building backward integration into Penicillin-G and 6-APA intermediates (above 10,000 MT output at over 80% capacity utilisation, with external sales commenced in Q4 FY26) and is constructing a biologics CDMO business under TheraNym with 120,000L of mammalian cell culture capacity — described as the largest such facility in India, with first revenues from Unit-1 expected in 2028 and Unit-2 in 2031. Recent strategic moves include the completed acquisition of US-based Lannett (adding a Seymour, Indiana facility with capacity for about 4 billion doses annually and over 400 employees), a non-exclusive voluntary licensing agreement with MSD for an HIV prevention drug covering 129 low- and middle-income countries, and an 80% stake in CRO A1 Biochem Labs. The biggest cost line is materials at 30.6% of revenue, followed by other operating expenses at 24.2% and employee costs at 15.4%, with capex running at 8% of revenue to fund new capacity. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. US formulations, Europe formulations, Growth markets formulations, India domestic formulations, Active Pharmaceutical Ingredients (APIs), Biologics CDMO (TheraNym / CuraTeQ), Specialty and injectables. Vertically integrated global generics and APIs manufacturer expanding into biologics CDMO and complex generics, with capex at 8% of revenue funding new capacity.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 23,455 | 24,855 | 29,002 | 31,724 | 33,653 |
| EBITDA (ex other income) | 4,259 | 3,719 | 5,651 | 6,583 | 6,780 |
| margin % | 18.2 | 15.0 | 19.5 | 20.8 | 20.1 |
| Owners' profit | 2,648 | 1,928 | 3,173 | 3,486 | 3,505 |
| EPS, as reported (₹) | 45.19 | 32.90 | 54.16 | 59.81 | 60.34 |
| ROE % · ROCE % | 10.8 · 13.4 | 7.2 · 9.7 | 10.6 · 14.3 | 10.7 · 15.8 | 9.2 · 13.6 |
| Debt / equity (x) | 0.10 | 0.18 | 0.21 | 0.24 | 0.20 |
| Cash from operations | 5,016 | 2,387 | 2,435 | 3,925 | 5,526 |
| Capex | (2,053) | (2,404) | (2,780) | (1,968) | (2,686) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 7,796 | 7,979 | 8,382 | 7,868 | 8,286 | 8,646 | 8,853 | 9,150 |
| Profit before tax | 1,207 | 1,198 | 1,367 | 1,205 | 1,274 | 1,338 | 1,293 | 1,517 |
| Net profit | 817 | 846 | 903 | 824 | 848 | 910 | 921 | 1,032 |
| EPS (₹) | 14.00 | 14.56 | 15.56 | 14.20 | 14.61 | 15.67 | 15.86 | 17.86 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,41,471 | 36.5 | 5.26 | 23.7 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,47,033 | 84.6 | 14.74 | 63.7 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,062 | 79.3 | 9.56 | 41.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,11,686 | 24.9 | 3.78 | 14.5 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · US FDA inspection at Aurobindo subsidiary Unit-IV ends with zero observations | regulatory legal | high | — | — |
| 11 Sept 2026 · Participation in J.P. Morgan India Investor Conference on Sep 22, 2026 | board shareholder meetings | low | — | — |
| 11 Sept 2026 · Aurobindo Pharma to attend BofA 2026 Asia Pacific Conference in Hong Kong | board shareholder meetings | low | — | — |
| 11 Sept 2026 · Aurobindo Pharma to attend Emkay Global investor meeting on Sept 17 | board shareholder meetings | low | — | — |
| 11 Sept 2026 · Participation in Kotak Healthcare Forum 2026 on September 18 | board shareholder meetings | low | — | — |
| 11 Sept 2026 · Aurobindo Pharma to meet ICICI Securities investors on Sept 17 | board shareholder meetings | low | — | — |
| 3 Sept 2026 · Aurobindo Pharma files IEPF share transfer newspaper notice | compliance | minimal | — | — |
| 1 Sept 2026 · Aurobindo Pharma incorporates new wholly owned subsidiary Avogent Lifesciences | strategic transactions | low | — | — |
| 31 Aug 2026 · Aurobindo's Lannett launches generic Advair Diskus in US market | compliance | low | — | — |
| 28 Aug 2026 · US FDA inspection at Unit-VI concluded with three procedural observations | capex operations | high | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| 17.3 |
| 18.0 |
| 12.4 |
| 25.2 |
| CIPLA LTD | 1,10,352 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,06,375 | 97.2 | 19.59 | 59.3 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 97,319 | 30.1 | 2.55 | 13.1 | 10.9 | 13.0 | 12.1 | 15.0 |
| AUROBINDO PHARMA LTD ◆ | 96,656 | 26.3 | 2.55 | 13.4 | 9.2 | 12.6 | 6.3 | 23.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 26.3 | 28.9 | 75 of 169 | 56% |
| P/B | 2.5 | 3.3 | 66 of 163 | 59% |
| ROCE | 12.6 | 10.8 | 80 of 183 | 57% |
| ROE | 9.3 | 10.4 | 94 of 171 | 45% |
| Debt / Equity | 0.2 | 0.1 | 102 of 171 | 41% |
| EBITDA margin | 23.0 | 17.5 | 63 of 165 | 62% |
| Revenue growth | 16.3 | 16.3 | 81 of 161 | 50% |
| Profit growth | 25.2 | 30.9 | 85 of 158 | 47% |
| Market cap | 96656 | 839 | 8 of 182 | 96% |
| A rating (BUY / ADD / REDUCE / SELL) |
| A state: the latest filed quarter and the measured reactions |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
